Takeda Pharmaceutical Company Limited

Sony Corporation

Eiji Kimura

Tatsuki Koike

Masaki Ogino

Norihito Tokunaga

Yoshiteru Ito

Masato Yoshikawa

Shinkichi Suzuki

Yuichi Kajita

Yuhei Miyanohana

Tomoaki Hasui

Takeshi Wakabayashi

Yasushi Hattori

Yasutaka Hoashi

Masami Yamada

Haruhi Ando

Tomohiro Kaku

Yuya Oguro

Shigemitsu Matsumoto

Mitsuhiro Ito

Shuhei Ikeda

Jinichi Yonemori

Taku Kamei

Makoto Fushimi

Toshiya Nishi

Izumi Nomura

Yasuhisa Kohara

Marilena Pira

Tomoko Ohashi

Hiromi Fukuda

Minoru Nakamura

Hiroki Sakamoto

Makoto Kamata

Hiromi Kobayashi

Takahiro Sugimoto

Takuto Kojima

Toshihiro Imaeda

Tomohiro Okawa

Masataka Murakami

Ikuo Fujimori

Kohei Takeuchi

Jun Kunitomo

Kenichiro Shimokawa

Morihisa Saitoh

Fumio Itoh

Yuta Tanaka

Tomohiro Kawamoto

Tomohiro Ohashi

Akira Konno

Alexander Martin Pawliczek

Tomoko Ashizawa

Katsuhito Murase

Ryosuke Arai

Javier Miguelez-Ramos

Kei Masuda

Kouji Fuji

Yuki Hanya

Taiki Hori

Hiroki Iwashita

Martin Alexander Pawliczek

Noriyuki Tezuka

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Heterocyclic compound

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

Pyrrolo[1,2-c]imidazole derivatives as orexin type 2 receptor agonists

Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.

Aromatic ring compound

The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification. 

Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.

Nitrogen-containing heterocyclic compound

Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.

An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present invention relates to a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.

Heterocyclic compounds having cholesterol 24-hydroxylase activity

The present invention relates to a compound represented by the formula (I), which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. In the formula (I), each symbol is as defined in the specification. 

The present invention provides a compound or a salt thereof useful for an agent for the prophylaxis or treatment of neurodegenerative disease and the like. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

An information processing device is provided which includes a detection portion that detects an approach or a touch of an operating body and that is provided on an external surface of a housing having a first housing and a second housing that is openably/closably attached to the first housing, a storage portion that stores detection information detected by the detection portion and a blinking pattern, and a blinking control portion that controls blinking of a light emitting portion based on the detection information detected by the detection portion and on the blinking pattern. With this configuration, results of detection by the detection portion can be notified to the user by the light emitting portion.

Information processing device, information notification method and computer program

For the purpose of providing a GSK-3&#x3b2; inhibitor containing an oxadiazole compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3&#x3b2;-related pathology or disease, the present invention provides a GSK-3&#x3b2; inhibitor containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

GSK-3&#x3b2; inhibitor

Growing community of inventors

Kanagawa, Japan

Eiji Kimura